SavedAdd your journal

Journals / Atatürk Üniversitesi Diş Hekimliği Fakültesi Dergisi / 2008 / Cilt: 18 - Sayı: 3

Osteonecrosis of the jaws related to bisphosphonate used for the treatment of bone metastatic prostate cancer: A case report and review of the literature

Kemik metastazı yapmış prostat kanseri tedavisinde kullanılan bifosfonata bağlı olarak çene kemiklerinde gelişen osteonekroz: Vaka raporu ve literatür derlemesi

Zafersoy Zühre AKARSLAN
Altundağ Sevil KAHRAMAN
Pages
105–110
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The aim of this article is to report a case of bisphosphonate related osteonecrosis of the mandible due to the treatment of bone metastatic prostate cancer and to assess the diagnois and treatment modalities according to current literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The aim of this article is to report a case of bisphosphonate related osteonecrosis of the mandible due to the treatment of bone metastatic prostate cancer and to assess the diagnois and treatment modalities according to current literature.
📊
Key Findings & Data:The aim of this article is to report a case of bisphosphonate related osteonecrosis of the mandible due to the treatment of bone metastatic prostate cancer and to assess the diagnois and treatment modalities according to current literature.
💡
Conclusion & Impact:The aim of this article is to report a case of bisphosphonate related osteonecrosis of the mandible due to the treatment of bone metastatic prostate cancer and to assess the diagnois and treatment modalities according to current literature.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The aim of this article is to report a case of bisphosphonate related osteonecrosis of the mandible due to the treatment of bone metastatic prostate cancer and to assess the diagnois and treatment modalities according to current literature.

Özet

Bu makalenin amacı, kemik metastazı yapmış olan prostat kanseri tedavisinde kullanılan bifosfonatlara bağlı olarak mandibulada osteonekroz gelişen bir vakanın sunulması, osteonekrozun teşhis ve tedavisine yönelik uygulamaların güncel literatür bilgisi ışığında değerlendirilmesidir.

🔖

Cite This Article

AKARSLAN, Z. Z., KAHRAMAN, A. S. (2022). Osteonecrosis of the jaws related to bisphosphonate used for the treatment of bone metastatic prostate cancer: A case report and review of the literature. Atatürk Üniversitesi Diş Hekimliği Fakültesi Dergisi, Cilt: 18 - Sayı: 3, 105–110. https://ajindex.com/articles/452706

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001
  2. 27(3): 165-76. 2-Gracia-Sanez JA, Lopez-Tarruella S, Gracia-Paredes B, Rodriguez-Lajusticia L, Villalobos L, Diaz-Rubio E. Osteonecrosis of the jaw as an adverse bisphosphonate event: Three cases of bone metastatic prostate cancer patients treated with zoledronic acid. Med Oral Pathol Oral Cir Bucal 2007
  3. 12(5): E351-6. 3-Dearnaley DP, Sydes MR, Mason MD, Stott M, Powell CS, Robinson AC, Thompson PM, Moffat LE, Naylor SL, Parmar MK. A double blind, placebo controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (mrc pr05Trail). J Natl Cancer 2003
  4. 95(17): 1300-11. 4-Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002
  5. 4(1):30-4. 5-Fleish H. Bisphosphonates: mechanisms of action. Endocr Rev 1998
  6. 19(1): 80-100. 6-Lobato JV, Mauricio AC, Rodgigues JM, Cavaleiro MV, Cortez PP, Xavier L, Botelho C, Hussain NS, Santos JD. Jaw avasculer osteonecrosis after treatment of multiple myeloma with zoledronate. J Plast Reconstr Aesthet Surg 2008
  7. 61(1):99-106. 7-Walter C, Grötz GA, Kunkel M, Al-Nawas B. Prevlance of bifosfonat associated osteoncrosis of the jaw within field of osteonecrosis. Support Care Cancer 2007
  8. 15(2): 197-202. 8-Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996
  9. 18(2): 75-85. 9-Hughes DE, MacDonald BR, Russell RG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 1989
  10. 83(6): 1930-5. 10-Hughes DE, Wright KR Uy HL. Sasaki A, Yoneda T. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Mineral Res 1995
  11. 10(10): 1478-87. 11-Murakami H, Takahashi N, Sasaki T, Udagawa N, Tanaka S, Nakamura I, Zhang D, Barbier A, Suda T. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 1995
  12. 17(2): 137-44. 12-Reilly MM. Osteonecrosis of the jaw in a patient receiving bisphosphonate therapy. Oncol Nurs Forum 2007
  13. 34(2):301-5. 13-Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005
  14. 23(34):8580-7. 14-Woo SK, Hellstein JW, Kalmar JR.